In a report released today, Joseph Stringer from Needham maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $60.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Stringer has given his Buy rating due to a combination of factors that highlight the promising potential of Ionis Pharmaceuticals. The company recently launched two new products, Tryngolza and Wainua, which are expected to contribute positively to its revenue growth. Additionally, Ionis has upcoming clinical readouts for SHTG and ATTR-CM, which could further enhance its market position if successful.
Furthermore, the company’s pipeline includes promising assets such as donidalorsen and ION582, which are in various stages of development and could offer significant future revenue streams. The strategic insights shared by key executives during the Needham Healthcare Conference underscore the company’s robust research capabilities and strategic direction, reinforcing the Buy recommendation.
In another report released on April 4, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $45.00 price target.